Sarcoma News

Mike Schmidt always felt a sense of invincibility as a professional athlete.

Basic research in immunotherapy and precision medicine remains at the forefront of progress in cancer treatment; however, a strong bipartisan commitment from Congress is needed to continue this progress, according to the seventh annual AACR Cancer Progress Report.

Pazopanib demonstrated promising rates of PFS among patients with liposarcoma, according to results of a prospective phase 2 study.

MADRID — Adjuvant treatment with imatinib improved outcomes among patients with high-risk gastrointestinal stromal tumors, according to final results of a randomized phase 3 trial presented at the European Society for Medical Oncology Congress.

The FDA accepted the resubmission of a new drug application for lutetium Lu 177 dotatate for treatment of adults with unresectable or metastatic, progressive, well-differentiated, somatostatin receptor-positive neuroendocrine tumors.

Overall risk for secondary cancers after Kaposi sarcoma decreased over time; however, acute lymphocytic leukemia and cancers of the tongue and penis became new common secondary cancers, according to results of a longitudinal analysis.

The FDA granted orphan drug designation to five agents under investigation for the treatment of solid tumors.

The NIH established the Kids First Data Resource Center, a pediatric cancer and rare disease data program that will enable clinicians and researchers to collaborate and access multiple genomic datasets.

Older patients with cancer often reported having better physical function, mental health and social support than their caregivers’ assessments, according to study results published in The Oncologist.

One-third of insured patients with cancer had out-of-pocket costs that exceeded their expectations, according to study results.